APOLLOMICS INC-27 (APLMW) Stock News

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to bring in $10 million upfront...

Mentions: APLM

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Mentions: APLM

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Mentions: APLM

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China,...

Mentions: APLM

Apollomics 公布 Uproleselan 在中國治療復發或難治性急性髓系白血病患者的第 3 期銜接性試驗的主要結果

福特斯城，加州, Dec. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (「Apollomics」或「該公司」) 是一家後期臨床生物製藥公司，開發多種腫瘤候選藥物以解決難治性和對治療有抗藥性的癌症。該公司今日公布了其藥物...

Mentions: APLM

Apollomics 公布在中国对复发或难治性急性髓系白血病患者进行的 Uproleselan III 期桥接试验主要结果

加利福尼亚州福斯特城, Dec. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (简称 “Apollomics” 或 “公司”)...

Mentions: APLM

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...

Mentions: APLM

Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company...

Mentions: APLM

Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Mentions: APLM

Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024...

Mentions: APLM

Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024

Mentions: APLM

Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024

Vebreltinib is efficacious in both treatment naïve and previously treated patients with NSCLC with METex14 skipping, and regardless of co-occurring MET amplification

Mentions: APLM

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...

Mentions: APLM

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Mentions: APLM

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Continued clinical progress for the vebreltinib registration-enabling program, including new data in non-CNS MET fusion tumors and non-small cell lung...

Mentions: APLM

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Mentions: APLM

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses)...

Mentions: APLM

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with solid tumors harboring MET gene fusions

Mentions: APLM

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

FOSTER CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...

Mentions: APLM

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

Mentions: APLM

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Mentions: APLM

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...

Mentions: APLM

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need...

Mentions: APLM

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need

Mentions: APLM

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying MET-driver alterations

Mentions: APLM

Apollomics Announces Presentation at the 2024 BIO International Convention

Mentions: APLM

Apollomics Announces Private Placement Financing and Addition to Board of Directors

Mentions: APLM

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics’ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the...

Mentions: APLM

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Mentions: APLM

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming...

Mentions: APLM

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancer

Mentions: APLM

Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mentions: APLM

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan...

Mentions: APLM

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Mentions: APLM

Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

Mentions: APLM

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company...

Mentions: APLM

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Mentions: APLM

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company...

Mentions: APLM

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Mentions: APLM